Blog: The Clinical Utility of Objective Convergence Measures in Concussion Assessment

This month, we’ll be introducing our newest concussion product feature, the objective convergence measurement. This assessment paradigm features automated measures of both eyes as they follow a target as it moves from distance to the Near Point of Convergence and back to the start position.

Read article

Blog: Digital Health and CNS Trials: A Promising Future Together

Much has been written and discussed about the impact that Digital Health is having on the evolution of clinical trials. While many agree that the COVID pandemic has greatly accelerated this process, others are split on the long-term impact Digital Health technologies project to ultimately have on patient outcomes.

Read article

Blog: The Provider Dilemma – Accelerating Digital Health Technology Adoption

While the pandemic is often credited with the accelerated adoption of digital health technologies among healthcare systems, particularly over the past two years, the competition among these organizations remains in its infancy.

Read article

Blog: The Five Ways Augmented Reality (AR) will Disrupt the Care of Vestibular Disorders

Dizziness related disorders are one of the most common forms of disability impacting quality of life today. Prevalent more among adults as they advance in age, dizziness has become one of the most commons type of chronic disabilities, affecting between 9-11% of the population.

Read article

SyncThink Announces Key Additions to Clinical Advisory Board

Palo Alto and Boston – March 29, 2022– SyncThink, a next gen neurotechnology company and developer of the award-winning EYE-SYNC technology, announces today the expansion of its clinical advisory board and the creation of a specific advisory panel of Physical Therapy providers, to assist the company with growing product demand and market opportunities.

Read article

Blog: EYE-SYNC and the Pico Neo 3 Pro Eye: Advancing VR for Healthcare

This month, we’ll be launching the newest integrated Virtual Reality (VR) headset from our partners at Pico Interactive, the Neo 3 Pro Eye.

Read article

SyncThink Expands Pico Partnership and Virtual Reality Headset Availability with Neo 3 Pro Integration

Palo Alto and Boston–March 9, 2022– SyncThink, a next gen neurotechnology company and developer of the award-winning EYE-SYNC technology, announces today the expansion of its partnership with Pico Interactive, a global technology company that develops innovative VR and enterprise solutions, and the integration of its platform onto the Pico Neo 3 Pro Eye headset.

Read article

Blog: The Consumerization of Digital Health

As technological innovation continues to outpace the evolution of healthcare practices, a fundamental shift is occurring. Patient centered care is no longer, having been replaced by consumer directed care. Consumers have shifted away from reactionary “sick” care options, opting to instead gravitate towards technology to monitor their own health and wellness.

Read article

Blog: 2021 – A Year In Review

For many of us, 2021 can be summed up in just a few words.

Unpredictable. Scary. Chaotic. Promising. Hopeful.

Whatever your preference, it is likely we can agree that these uncertain times has forced all of us to think outside the box, to adapt to changing circumstances, and to learn new things and to do them in unique ways. We at SyncThink…

Read article

Blog: A Message From Our Founder

Our recent FDA clearance allowing EYE-SYNC as an aide to concussion diagnosis is a major milestone for diagnostic eye-tracking technology and its use in measuring prediction, a key brain function. SyncThink has spent decades studying this through rigorous clinical research, in order for patients and clinicians to benefit from the use of reliable, objective data to identify prediction related deficits, which are often discovered for the first time.

Read article

SyncThink Receives Second FDA Clearance for EYE-SYNC Platform; the First Mobile, Rapid Test for Concussion

Palo Alto and Boston—October 5, 2021— SyncThink, a next gen neurotechnology company and developer of the award-winning EYE-SYNC technology, announces today the US Food and Drug Administration (FDA) has granted clearance of the EYE-SYNC technology as an Aid to Concussion, or mild Traumatic Brain Injury (mTBI) Diagnosis. EYE-SYNC previously received the prestigious Breakthrough Device Designation from the FDA in 2019, following the initial clearance and commercialization of the technology platform in 2017.

Read article

Blog: Finding the Keys to Scalability – Democratizing Brain Health Assessment

June 3, 2021 In cased you missed it, check out our feature on us written by our partners at Tobii: https://blog.tobii.com/seeking-out-the-keys-to-scalability-to-democratize-brain-health-assessment By Maggie Ma For this innovation story, I sat with Scott Anderson, chief clinical officer at SyncThink — an expanding Palo-Alto tech company that has recently launched the third generation of its brain health […]

Read article